Olink Holding AB (publ) (NASDAQ:OLK) Posts Earnings Results, Misses Estimates By $0.01 EPS

Olink Holding AB (publ) (NASDAQ:OLK - Get Free Report) announced its earnings results on Monday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports. Olink Holding AB (publ) had a negative return on equity of 7.00% and a negative net margin of 19.72%. The business had revenue of $28.75 million for the quarter, compared to analysts' expectations of $31.29 million.

Olink Holding AB (publ) Price Performance

Shares of Olink Holding AB (publ) stock traded up $0.29 during trading hours on Wednesday, hitting $24.01. The company had a trading volume of 692,586 shares, compared to its average volume of 609,189. The company's 50-day moving average is $23.33 and its two-hundred day moving average is $24.32. Olink Holding AB has a twelve month low of $14.10 and a twelve month high of $26.01. The company has a market cap of $2.99 billion, a P/E ratio of -88.92 and a beta of 0.50.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on OLK shares. Morgan Stanley reissued an "equal weight" rating and issued a $26.00 price objective on shares of Olink Holding AB (publ) in a research report on Tuesday, March 26th. Canaccord Genuity Group reissued a "hold" rating and issued a $26.00 price objective on shares of Olink Holding AB (publ) in a research report on Tuesday, March 26th.

About Olink Holding AB (publ)

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.